Coya Therapeutics, Inc. and Dr. Reddy's Laboratories Enter into an Exclusive Collaboration for Development and Commercialization of COYA 302, an Investigational Combination Therapy for Treatment of Amyotrophic Lateral Sclerosis (ALS)Business Wire • 12/06/23
Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial ResultsBusiness Wire • 11/08/23
Coya Announces Acceptance of Oral Presentation, “Regulatory T Cell Expansion Strategy to Target Inflammation in Alzheimer's Disease: A Phase 1 Feasibility Study,” at the 18th International Conference on Alzheimer's and Parkinson's Disease in LisbonBusiness Wire • 10/27/23
Coya Therapeutics (Coya) Announces Completion of Enrollment in a Well-Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer's Disease (AD)Business Wire • 10/09/23
Coya Therapeutics Presents New Experimental Data Supporting the Mechanism of Action of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium MeetingBusiness Wire • 10/05/23
Coya Therapeutics Announces the Presentation of Human Ex-Vivo Mechanistic Data Further Supporting the Development of COYA 302 for Amyotrophic Lateral Sclerosis (ALS) at the 22nd Annual Northeast ALS (NEALS) Consortium MeetingBusiness Wire • 10/03/23
Coya Therapeutics Licenses Exclusive Worldwide rights to Exosome Engineering Technology (EET) from Carnegie Mellon University (CMU)Business Wire • 09/22/23
Coya Therapeutics Successfully Engineers Regulatory T Cell (Treg) Derived Exosomes with CTLA-4 Protein to Selectively Target Immune Cells with Potential to Deliver Targeted Therapies Across Multiple DiseasesBusiness Wire • 09/07/23
Coya Therapeutics Announces Publication of Potential Novel Blood Biomarker Data in Amyotrophic Lateral Sclerosis (ALS) Patients That Accurately Reflect Therapeutic Responses When Treated with Regulatory T Cell (Treg) Enhancing TherapiesBusiness Wire • 08/31/23
Coya Therapeutics To Present Novel Proof of Concept Exosome Modification Technology at the 5th Exosome Based Therapeutic Development Summit in Boston, MA on September 7, 2023Business Wire • 08/25/23
Former CEO and Chairman of the Board of Bayer Pharma AG, Dieter Weinand, Joins Coya's Board of DirectorsBusiness Wire • 08/21/23
Capitalizing On Inflammation's Role In Neurological Disease Part 1: Coya TherapeuticsSeeking Alpha • 08/14/23
Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial ResultsBusiness Wire • 08/08/23
Coya Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023Business Wire • 08/03/23
Coya Therapeutics (“Coya”) Announces the Appointment of Dr. Merit Cudkowicz, M.D., M.Sc., as Clinical Advisor to Support the Development of COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Business Wire • 07/19/23
Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer's DiseaseBusiness Wire • 07/17/23
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian HepnerBusiness Wire • 07/05/23
Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer's Disease (AD) at the 2023 Alzheimer's Association International Conference (AAIC)Business Wire • 06/28/23
Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)Business Wire • 06/20/23
Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory AffairsBusiness Wire • 06/14/23
